The company operates a full-service hotel in Agra, India, generating revenue through room rentals, food and beverage sales, and hosting banquet events for tourists and business travelers.
The company lacks a durable competitive advantage, as evidenced by an average ROCE of 1.3% and negative ROE, which are significantly below the cost of capital. While the hotel is located near a major tourist landmark, the business operates in a highly fragmented and competitive market where it lacks the scale or brand power to generate excess returns.
Capital has been primarily directed toward maintaining the existing aging property and servicing debt. Returns on reinvested capital are negligible, and the company has not paid dividends, reflecting a lack of surplus value creation for shareholders.
The business succumbed to the 'leaky bucket' syndrome where revenue growth was consistently cannibalized by rising operational costs and maintenance capex for an aging asset. Despite being near a landmark, the lack of brand power meant the company could not raise prices to offset inflation, leading to a slow bleed of capital. The failure was cemented when related-party outflows and high executive pay drained the remaining liquidity, leaving the firm unable to modernize against newer, more efficient competitors, eventually resulting in a stranded asset that produced no yield for minority shareholders.
RichFakir rates Howard Hotels Ltd's business quality as poor — 22/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Howard Hotels Ltd is trading about 97% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Howard Hotels Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Howard Hotels Ltd's fair value is about ₹9 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →